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Aim: The aim of this study is to compare the safety, efficacy and durability of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor 
Resolute), BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of patients with left main coronary arteries (LMT) 
stenosis.
Methods: A prospective analysis of 1127 LMT stenosis (321 SES, 277 PES, 129 ZES-R, 172 BES, 55 ECS, 173 EES) in six high volume Asian centers 
after successful stenting in LMT stenosis was performed. The study endpoints were 30 days and 12 months major adverse cardiac events (MACE), 12 
months angiographic restenosis and target lesion revascularization (TLR) in those 6 groups.
Results: See table for clinical results.
Conclusion: The use of drug-eluting stents in patients with LMT stenosis was safe with low acute complication. Patients treated with BES and EES 
showed lesser rate of restenosis compared with ZES-R and ECS. 
SES PES ZES-R BES ECS EES
Number of patients 321 277 129 172 55 173
Procedural success (%) 100 100 100 100 100 100
MACE at 30 days (%) 0.3 0.4 0 0 0 0
Proximal RD (mean: mm) 3.8 3.7 3.8 3.8 3.9 3.8
Stenting procedure
(culotte/provisional-T/mini-crush)
44/167/110 66/110/101 21/69/39 23/83/66 8/29/18 43/68/62
MLD at baseline (mean: mm) 3.6 3.5 3.6 3.6 3.7 3.7
12 months MLD (mean: mm) 3.4 3.0 3.5 3.4 2.9 3.5
Restenosis rate (%) 8.7 10.8 14.0 7.0* 20.0 4.6*
TLR (%) 8.1 9.4 10.1 6.4* 18.2 4.6*
MACE (%) 8.4 9.8 10.1 6.4* 18.2 4.6*
RD: reference diameter, MLD: minimum lumen diameter, *p<0.05 vs. ZES-R and ECS.
